-

Viz.ai to Participate in Morgan Stanley 22nd Annual Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced Chris Mansi, M.D., CEO and Co-founder, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 4, 2024 at 1:05 p.m. ET in New York, NY.

Dr. Mansi will share how Viz.ai is transforming last mile delivery of AI-powered workflows in healthcare with a broadly deployed AI safety net to ensure no patient is missed, helping providers and life sciences to bridge care gaps and increase patient access to life-saving treatments. With the growing need to reinvent the pharmaceutical commercial model as the Inflation Reduction Act puts pressure on drug prices, Viz.ai’s AI-Powered Care Accelerator is uniquely positioned to guide more patients to the right diagnosis, specialist, and treatment faster.

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,600+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Viz.ai


Release Versions

Contacts

Social Media Profiles
More News From Viz.ai

Viz.ai and NCCN Collaborate to Integrate NCCN Guidelines into Clinical Workflows for Oncologists

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an agreement with the National Comprehensive Cancer Network® (NCCN®). This collaboration integrates NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast, Prostate, and Bladder Cancer into the Viz Oncology Platform making this important information readily available to clinicians when they’re making critical decisions about patient care. Thr...

Viz.ai Appoints Dr. Timothy N. Showalter as First Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the appointment of Tim Showalter, MD, MPH, MBA, as its first Chief Medical Officer (CMO). Dr. Showalter, an accomplished academic radiation oncologist, will lead Viz.ai’s clinical strategy and advance the company’s mission to use artificial intelligence to improve access to life-saving care. He will report to Chris Mansi, MD, CEO and co-founder of Viz.ai. Dr. Sho...

New Data Show Viz.ai’s AI-Enabled ECG Screening Increases Detection and Accelerates Diagnosis of Hypertrophic Cardiomyopathy

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how Viz HCM enables faster, accurate detection of hypertrophic cardiomyopathy (HCM), to help ensure that more patients are identified. Two studies, which will be presented at the American Heart Association (AHA) Scientific Sessions 2025, show Viz.ai’s real-world ability to identify more patients with HCM years earlier than current...
Back to Newsroom